Cost-effectiveness of a gestational age metabolic algorithm for preterm and small-for-gestational-age classification.


Journal

American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609

Informations de publication

Date de publication:
01 2021
Historique:
received: 10 04 2020
revised: 22 10 2020
accepted: 16 11 2020
entrez: 16 1 2021
pubmed: 17 1 2021
medline: 25 6 2021
Statut: ppublish

Résumé

Preterm birth complications are the leading cause of death among children under 5 years of age, and this imposes a heavy burden on healthcare and social systems, particularly in low- and middle-income countries where reliable estimates of gestational age may be difficult to obtain. Metabolic analyte data can aid in accurately estimating gestational age. However, important costs are associated with this approach, which are related to the collection and analysis of newborn samples, and its cost-effectiveness has yet to be determined. This study aimed to evaluate the cost-effectiveness of an internationally validated gestational age estimation algorithm based on neonatal blood spot metabolite data in combination with clinical and demographic variables (birthweight, sex, and multiple birth status) compared with a basic algorithm that uses only clinical and demographic variables in classifying infants as preterm or term (using a 37-week dichotomous preterm or term classification) and determining gestational age. The cost per correctly classified preterm infant and per correctly classified small-for-gestational-age infant for the metabolic algorithm vs the basic algorithm were estimated with data from an implementation study in Bangladesh. Over 1 year, the metabolic algorithm correctly classified an average of 8.7 (95% confidence interval, 1.3-14.7) additional preterm infants and 145.3 (95% confidence interval, 128.0-164.7) additional small-for-gestational-age infants per 1323 infants screened compared with the basic algorithm using only clinical and demographic variables. The incremental annual cost of adopting the metabolic algorithm was $100,031 (95% confidence interval, $86,354-$115,725). If setup costs were included, the cost was $120,496 (95% confidence interval, $106,322-$136,656). Compared with the basic algorithm, the incremental cost per preterm infant correctly classified by the metabolic algorithm is $11,542 ($13,903 with setup), and the incremental cost per small-for-gestational-age infant is $688 ($829 with setup). This research quantifies the cost per detection of preterm or small-for-gestational-age infant in the implementation of a newborn screening program to aid in improved classification of preterm and, in particular, small-for-gestational-age infants in low- and middle-income countries.

Sections du résumé

BACKGROUND
Preterm birth complications are the leading cause of death among children under 5 years of age, and this imposes a heavy burden on healthcare and social systems, particularly in low- and middle-income countries where reliable estimates of gestational age may be difficult to obtain. Metabolic analyte data can aid in accurately estimating gestational age. However, important costs are associated with this approach, which are related to the collection and analysis of newborn samples, and its cost-effectiveness has yet to be determined.
OBJECTIVE
This study aimed to evaluate the cost-effectiveness of an internationally validated gestational age estimation algorithm based on neonatal blood spot metabolite data in combination with clinical and demographic variables (birthweight, sex, and multiple birth status) compared with a basic algorithm that uses only clinical and demographic variables in classifying infants as preterm or term (using a 37-week dichotomous preterm or term classification) and determining gestational age.
STUDY DESIGN
The cost per correctly classified preterm infant and per correctly classified small-for-gestational-age infant for the metabolic algorithm vs the basic algorithm were estimated with data from an implementation study in Bangladesh.
RESULTS
Over 1 year, the metabolic algorithm correctly classified an average of 8.7 (95% confidence interval, 1.3-14.7) additional preterm infants and 145.3 (95% confidence interval, 128.0-164.7) additional small-for-gestational-age infants per 1323 infants screened compared with the basic algorithm using only clinical and demographic variables. The incremental annual cost of adopting the metabolic algorithm was $100,031 (95% confidence interval, $86,354-$115,725). If setup costs were included, the cost was $120,496 (95% confidence interval, $106,322-$136,656). Compared with the basic algorithm, the incremental cost per preterm infant correctly classified by the metabolic algorithm is $11,542 ($13,903 with setup), and the incremental cost per small-for-gestational-age infant is $688 ($829 with setup).
CONCLUSION
This research quantifies the cost per detection of preterm or small-for-gestational-age infant in the implementation of a newborn screening program to aid in improved classification of preterm and, in particular, small-for-gestational-age infants in low- and middle-income countries.

Identifiants

pubmed: 33451597
pii: S2589-9333(20)30272-X
doi: 10.1016/j.ajogmf.2020.100279
pmc: PMC7805344
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100279

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Références

Rev Obstet Gynecol. 2012;5(2):100-5
pubmed: 22866189
Am J Obstet Gynecol. 2016 Apr;214(4):515.e1-515.e13
pubmed: 26645954
Reprod Health. 2018 Jul 20;15(1):129
pubmed: 30029609
Elife. 2019 Mar 19;8:
pubmed: 30887951
Pediatrics. 2007 Apr;119(4):e866-74
pubmed: 17339387
Lancet. 2013 Aug 3;382(9890):417-425
pubmed: 23746775
Reprod Health. 2013;10 Suppl 1:S2
pubmed: 24625129
Int J MCH AIDS. 2020;9(1):103-120
pubmed: 32123634
Lancet. 2014 Sep 6;384(9946):857-68
pubmed: 25209487
Reprod Health. 2013;10 Suppl 1:S1
pubmed: 24625113
BMJ. 2017 Aug 17;358:j3677
pubmed: 28819030
BMC Pregnancy Childbirth. 2018 May 16;18(1):170
pubmed: 29769056
Am J Obstet Gynecol. 2016 Apr;214(4):511.e1-511.e13
pubmed: 26688490
Matern Child Nutr. 2016 May;12 Suppl 1:12-26
pubmed: 27187907
BJOG. 2015 Oct;122(11):1484-93
pubmed: 26111589
Genet Med. 2011 Mar;13(3):230-54
pubmed: 21325949
Am J Obstet Gynecol. 2016 Apr;214(4):513.e1-513.e9
pubmed: 26519781
Expert Rev Proteomics. 2019 Sep;16(9):727-731
pubmed: 31422714
Bull World Health Organ. 2005 Mar;83(3):178-85
pubmed: 15798841

Auteurs

Kathryn Coyle (K)

Department of Health Sciences, Institute of Environment, Health and Societies, Brunel University London, Kingston Lane, Uxbridge, Middlesex, United Kingdom.

Amanda My Linh Quan (AML)

Dalla School of Public Health, University of Toronto, Toronto, Ontario Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Lindsay A Wilson (LA)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Steven Hawken (S)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

A Brianne Bota (AB)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Doug Coyle (D)

Department of Health Sciences, Institute of Environment, Health and Societies, Brunel University London, Kingston Lane, Uxbridge, Middlesex, United Kingdom; Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

Jeffrey C Murray (JC)

Department of Pediatrics, University of Iowa, Iowa City, IA.

Kumanan Wilson (K)

Department of Medicine, University of Ottawa, Ottowa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Bruyère Research Institute, Ottawa, Ontario, Canada. Electronic address: kwilson@ohri.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH